Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) (Synonyms: GLYX-13 Trifluoroacetate) |
カタログ番号GC33492 |
ラパスチネル トリフルオロアセテート (GLYX-13 トリフルオロアセテート) (GLYX-13 トリフルオロアセテート) は、グリシン部位部分アゴニスト特性を持つ NMDA 受容体モジュレーターです。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1435786-04-1
Sample solution is provided at 25 µL, 10mM.
Rapastinel Trifluoroacetate is an NMDA receptor modulator with glycine-site partial agonist properties and currently in a phase II clinical development program as an adjunctive therapy for major depressive disorder.
Rapastinel Trifluoroacetate is an NMDA receptor modulator with glycine-site partial agonist properties and currently in a phase II clinical development program as an adjunctive therapy for major depressive disorder. Mice given Rapastinel Trifluoroacetate (1.0 mg/kg) prior to acute ketamine (30 mg/kg) show clear preference for novel compare to familiar objects (P0.05][2].
[1]. Rajagopal L, et al. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behav Brain Res. 2016 Feb 15;299:105-10. [2]. Burgdorf J, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015 Nov 12;308:202-11.
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *